Reuters
Search documents
US military shipbuilder Huntington Ingalls expects negative free cash flow in current quarter
Reuters· 2026-02-05 17:36
Core Viewpoint - U.S. military shipbuilder Huntington Ingalls reported that it anticipates negative free cash flow for the current quarter, despite exceeding quarterly profit estimates, which negatively impacted its share price [1] Group 1: Financial Performance - Huntington Ingalls beat quarterly profit estimates, indicating strong operational performance [1] - The expectation of negative free cash flow suggests potential liquidity challenges in the near term [1] Group 2: Market Reaction - The announcement of expected negative free cash flow led to a decline in the company's share price, reflecting investor concerns [1]
US House panel issue subpoena to Coupang as part of discrimination probe
Reuters· 2026-02-05 17:32
Core Point - The House Judiciary Committee has issued a subpoena to Coupang as part of an investigation into alleged discrimination against U.S. companies [1] Group 1 - The subpoena seeks communications between Coupang and other entities related to the ongoing probe [1]
How Glencore and Rio Tinto's core assets stack up
Reuters· 2026-02-05 17:27
Group 1 - Rio Tinto has abandoned a significant mining deal with Glencore for the third time [1]
Bayer says its experimental blood thinner cuts risk of stroke recurrence by 26%
Reuters· 2026-02-05 17:21
Core Insights - Bayer's experimental blood thinner has demonstrated a 26% reduction in the risk of stroke recurrence during a late-stage trial, providing a significant boost to the company's turnaround efforts led by CEO Bill Anderson [1] Company Summary - The positive results from the trial represent a critical advancement for Bayer in the pharmaceutical sector, particularly in the development of treatments for stroke prevention [1]
Spain's Sabadell names TSB's Armengol as new CEO, replacing Gonzalez-Bueno
Reuters· 2026-02-05 17:10
Spain's Sabadell announced on Thursday that Marc Armengol will replace Cesar Gonzalez-Bueno as the bank's new chief executive officer. ...
BP seeks partner for one of the oldest Iraqi oil fields, Bloomberg News reports
Reuters· 2026-02-05 17:08
Core Viewpoint - BP is seeking a partner to enhance production and share costs at one of the oldest oil fields in Iraq, as reported by Bloomberg News [1] Group 1 - BP aims to ramp up production at an aging Iraqi oil field [1] - The company is looking for a partner to help mitigate costs associated with the production increase [1]
Phillips 66 to cut jobs as Los Angeles refinery shuts, Bloomberg News reports
Reuters· 2026-02-05 17:03
Core Insights - Phillips 66 will lay off approximately half of its employees at its only remaining oil refinery in California following the closure of operations [1] Company Summary - The decision to shut down the refinery and reduce the workforce is part of a broader strategy to streamline operations amid changing market conditions [1] - The layoffs will significantly impact the local economy, given the refinery's role as a major employer in the region [1] Industry Summary - The closure of the refinery reflects ongoing challenges in the oil refining sector, including fluctuating demand and regulatory pressures [1] - This move may signal a trend of consolidation within the industry as companies adapt to evolving market dynamics [1]
Italy's Banco BPM beats FY profit on stronger fee income
Reuters· 2026-02-05 16:57
Banco BPM on Thursday reported a 2025 net profit that beat market expectations, as a surge in fees more then offset the impact of a decline in lending income. ...
Shell weighing Venezuela offshore investments worth billions of dollars, CEO tells CNBC
Reuters· 2026-02-05 16:55
Group 1 - Shell is considering investments in offshore natural gas opportunities in Venezuela, with potential investments amounting to a few billion dollars [1] - Production from these investments is expected to commence within the next couple of years [1]
CVS Health to drop Amgen and Lilly's bone disease treatments from some drug lists
Reuters· 2026-02-05 16:55
Core Viewpoint - CVS Health will replace Amgen and Eli Lilly's bone disease treatments with lower-cost alternatives in its preferred drug lists starting April 1 [1] Group 1 - CVS Health is making changes to its preferred drug lists to include more cost-effective options [1] - The decision reflects a broader trend in the healthcare industry towards reducing drug costs for consumers [1]